ACIU

AC Immune SA is a Swiss clinical-stage biopharmaceutical company focused on developing therapeutic and diagnostic products for neurodegenerative diseases, particularly Alzheimer's disease. Headquartered in Lausanne, Switzerland, the company operates through its proprietary technology platforms including Morphomer, SupraAntigen, and Conformer, which target misfolded proteins associated with neurological conditions. AC Immune's pipeline includes multiple product candidates in various stages of development, with lead programs focusing on anti-tau and anti-amyloid beta therapies. The company maintains strategic partnerships with major pharmaceutical companies including Janssen Pharmaceuticals, Genentech, and Eli Lilly, which provide funding and development support for several of its programs. These collaborations have generated significant milestone payments and allow AC Immune to advance multiple candidates simultaneously while sharing development risks. The company employs approximately 150 people and operates research facilities in Switzerland. Recent developments include advancing semorinemab, an anti-tau antibody developed with Genentech, through Phase II trials, and progressing its phospho-tau vaccine candidate ACI-7104 into clinical development. AC Immune went public on NASDAQ in 2016 and maintains a dual listing. The company focuses on addressing the substantial unmet medical need in Alzheimer's and other neurodegenerative diseases, where few effective treatment options currently exist for the millions of patients affected globally.